XORTX Therapeutics Inc. (XRTX)
Market: NASD |
Currency: USD
Address: 3710 – 33rd Street NW
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
Show more
📈 XORTX Therapeutics Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
50-100%
-
Revenue Growth Range (1Y):
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2023 |
- |
$0.111111 |
- |
2023-11-14 |
- |
Stock split |
| $0.111111 |
- |
2023-11-10 |
- |
Stock split |
|
Total Amount for 2023: $0.222222 |
📅 Earnings & EPS History for XORTX Therapeutics Inc.
| Date | Reported EPS |
|---|
| 2026-03-30 (estimated upcoming) | - |
| 2025-11-12 (estimated upcoming) | - |
| 2025-11-11 (estimated upcoming) | - |
| 2025-08-12 (estimated upcoming) | - |
| 2025-08-11 (estimated upcoming) | - |
| 2025-05-14 | - |
| 2025-05-13 | - |
| 2025-03-31 | - |
| 2025-03-30 | - |
| 2022-11-10 | - |
| 2022-11-09 | - |
| 2022-08-11 | -0.12 |
| 2022-08-10 | -0.12 |
| 2022-05-12 | -0.26 |
| 2022-04-12 | - |
| 2022-04-11 | - |
📰 Related News & Research
No related articles found for "xortx therapeutics".
